RGS5 and metabolic dysfunction-associated steatohepatitis: As shown in Figure 3C, RGS5 protein expression was suppressed in NAFLD/NASH cells but was recovered effectively by resmetirom treatment, and the phosphorylation of both STAT3 and NF-κB, which were activated in NAFLD/NASH, was significantly attenuated by resmetirom treatment.